In continuation to the scientific discussions on COVID-19 vaccines research, WHO R&D Blueprint organized a consultation to review emerging data related to the omicron variant. This consultation took place on Wednesday, 15 December 2021 from 14h30 to 17h30 (CET) Geneva time.
Invited experts will included:
- Leading researchers on COVID-19 neutralization studies
- Global experts on evidence synthesis and critical appraisal of evidence
During this consultation, global experts reviewed the available evidence, critically appraised the data, and summarized the interpretation of evidence and next steps.
PRESENTATIONS
Session 1: Interpreting immunological and animal studies
Session 2: Emerging Data
- Further studies on SARS-CoV-2 variants
- Omicron neutralization
- Omicron Sensitivity to mRNA-1273 Induced Neutralizing Antibodies
- Reduced Neutralization of SARS-CoV-2 Omicron Variant by Vaccine Sera and Monoclonal Antibodies
- Variable loss of antibody potency against Omicron
- Comparison of Wild type and Omicron variant in plaque reduction neturalization tests: Sera from BNT162b2, CoronaVac and Convalescent sera
- B.I.I.529 escapes the majority of SARS-CoV-2 neutralizing antibodies of diverse epitopes
- CD8+ T cell responses and SARS-CoV-2 variants
- Human serum from SARS-CoV-2 vaccinated and COVID-19 patients shows reduced binding to the RBD of SARS-CoV-2 Omicron variant
- SARS-CoV-2 variants vs antibodies
- Omicron – neutralisation, ADCC responses and immune escape
- Omicron virus isolate
- Omicron in Israel
- SARS-CoV-2 B.1.1.529 variant (Omicron) evades neutralization by sera from vaccinated and convalescent individuals
- Neutralising antibody concentrations following 2 doses of Pfizer and AstraZeneca COVID vaccines
- Preliminary experimental data on T cell cross-reactivity to Omicron
Summary
Watch the meeting recording here:
WHO TOOLS AND RESOURCES
RECORDINGS, PRESENTATIONS, AND MEETING REPORTS